Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib.

Front Oncol · 2021 · PMC8564482 · PMID 34745989

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)

Results showed a trend ( p = 0.08) in the reduction in the endocytic capacity of DCs treated with Cabozantinib compared to the not treated cells, suggesting a more mature status of the cells cultured in the presence of the drug.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.